DMAA
DMAA Brand names, DMAA Analogs
DMAA Brand Names Mixture
- No information avaliable
DMAA Chemical_Formula
C12H21N
DMAA RX_link
http://www.rxlist.com/cgi/generic3/namenda.htm
DMAA fda sheet
DMAA msds (material safety sheet)
DMAA Synthesis Reference
No information avaliable
DMAA Molecular Weight
179.302 g/mol
DMAA Melting Point
258 oC (HCl salt)
DMAA H2O Solubility
35 mg/mL (HCl salt), 0.9 mg/mL for free base
DMAA State
Solid
DMAA LogP
2.197
DMAA Dosage Forms
Tablet
DMAA Indication
For the treatment of moderate to severe dementia of the Alzheimer's type.
DMAA Pharmacology
Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer's disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.
DMAA Absorption
Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
DMAA side effects and Toxicity
Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
DMAA Patient Information
Information for Patients and Caregivers: Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).
DMAA Organisms Affected
Humans and other mammals
